Eurand Industrial Award Honors Achievement in Drug Delivery Research

7/16/2008, 10:22 PM (Source: GlobeNewswire)
Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this

MILAN, Italy, July 16, 2008 (PRIME NEWSWIRE) -- Eurand N.V.
(Nasdaq:EURX) and the Controlled Release Society (CRS) announced
today that the 2008 Eurand Industrial Award has been presented to
distinguished research scientist Felix Theeuwes, D. Sc., in
recognition of his achievements in the field of the delivery of
bioactives and for his exceptional contributions to the industry.

An independent judging panel, composed of internationally recognized,
drug-formulation experts, unanimously selected Theeuwes for his
invention of the ALZET(r) and OROS(r) technologies. ALZET(r) Osmotic
Pumps are miniature infusion pumps for the continuous dosing of
laboratory animals as small as mice and young rats. These minipumps
provide researchers with a convenient and reliable method for
controlled agent delivery in vivo. OROS(r) extended-release
technology employs osmosis to provide concise, controlled drug
delivery and is utilized in several high-profile extended release
prescription products for the treatment of angina/hypertension,
Attention Deficit Hyperactivity Disorder (ADHD), overactive bladder,
allergy symptoms, hyperglycemia and bronchospasm.

"Eurand is pleased to honor Dr. Theeuwes for his long-standing
personal and professional commitment to drug delivery," said Stephen
Perrett, Director of Corporate Technologies and Product Portfolio for
Eurand. "We hope that the Eurand Industrial Award, now in its ninth
year, continues to inspire researchers around the world to strive for
innovations that address the many complex questions we face in
improving drug delivery."

Theeuwes is Chair, Co-Founder, and Chief Scientific Officer of DURECT
Corporation. Theeuwes was with ALZA Corporation from 1970 until 1999,
where he invented the ALZET(r) mini osmotic pump and invented and led
the development of the OROS(r) technology and related products. He
directed research and development in transdermal products, the
electrotransport/iontophoresis program, and the DUROS(r) osmotic
implant program. Theeuwes holds more than 210 U.S. patents covering
these systems and has published more than 80 articles and book

The Eurand Industrial Award, sponsored by Eurand and presented each
year in conjunction with the Controlled Release Society Annual
Meeting and Exposition, recognizes innovations in oral drug delivery
and the longstanding commitment to the improvement of drug
formulations. Established in 2000, it is regarded as a premier
industry award and is designed to encourage, recognize and reward
innovative approaches in oral drug delivery. The Eurand Award is
presented to the most innovative scientists in the field for their
outstanding research efforts and for their work in advancing oral
drug delivery.

About Eurand

Eurand is a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation
technologies. Eurand has had four partnered products approved by the
FDA since 2001 and has a pipeline of product candidates in
development for itself and its collaboration partners. Eurand
completed two phase III clinical trials for EUR-1008 (Zentase),
intended for the treatment of Exocrine Pancreatic Insufficiency and,
as announced on June 18, 2008, received an approvable letter from the
FDA for its NDA for this product. Eurand's technology platforms
include bioavailability enhancement of poorly soluble drugs,
customized release, taste-masking/fast-dissolving formulations and
drug conjugation.

Eurand is a global company with facilities in the U.S. and Europe.
For more information, visit Eurand's website at

This release, and oral statements made with respect to information
contained in this release, constitutes forward-looking statements.
Such forward-looking statements include those which express plan,
anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical fact
including, but not limited to the status of our NDA filing and the
plans for MAA filing relating to EUR-1008, enrollment and future
plans for our clinical trials, progress of and reports of results
from clinical studies, clinical development plans and product
development activities. The words "potentially," "could," "calls for"
and similar expressions also identify forward-looking statements.
These statements are based upon management's current expectations and
are subject to risks and uncertainties, known and unknown, which
could cause actual results and developments to differ materially from
those expressed or implied in such statements. Factors that could
affect actual results include risks associated with the possibility
that the FDA does not approve our NDA or delays approval; the outcome
of any discussions with the FDA; and unexpected delays in preparation
of materials for submission to the FDA as a part of our NDA filing.
Forward-looking statements contained in this press release are made
as of this date, and we undertake no obligation to publicly update
any forward-looking statement, whether as a result of new
information, future events or otherwise. Actual events could differ
materially from those anticipated in the forward-looking statements.

Schwartz Communications
Media Contact:
Caitlin Hunt
+1 781 684 0770

--- End of Message ---

Eurand N.V.
845 Center Drive Vandalia, Ohio USA

Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.